Zacks Small-Cap Research
Sponsored – Impartial - Comprehensive

January 14, 2025
David Bautz, PhD
312-265-9471
dbautz@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

Soligenix, Inc.

(SNGX-NASDAQ)

SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL…

Based on our probability adjusted DCF model that takes into account potential future revenues from HyBryte™, SGX302, and SGX945, SNGX is valued at $35.00 per share. This model is highly dependent upon continued clinical success of the company's pipeline and will be adjusted accordingly based upon future clinical results.

Current Price (01/14/25)	$3.13
Valuation	**$35.00**

OUTLOOK

On January 14, 2025, Soligenix, Inc. (SNGX) announced additional interim data from the open-label, investigator-initiated study (IIS) testing HyBryte treatment in patients with cutaneous T cell lymphoma (CTCL) for up to 12 months. Thus far, nine patients have been enrolled and treated with HyBryte for up to 54 weeks. Over 80% (5/6 that have completed at least 18 weeks of therapy) have already achieved treatment success, which is defined in the study protocol as a ≥50% improvement in the cumulative mCAILS. Of the five treatment successes, two achieved a "complete response" by 18 weeks. The study is continuing to enroll patients and is being supported by a $2.6 million grant from the FDA. In addition to this study, the company recently announced the initiation of the 80-patient FLASH2 Phase 3 trial with updates expected throughout 2025.

SUMMARY DATA

52-Week High	**$13.86**
52-Week Low	**$2.00**
One-Year Return (%)	**-76.66**
Beta	**1.77**
Average Daily Volume (sh)	**37,443**
Shares Outstanding (mil)	**3**
Market Capitalization ($mil)	**$8**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**4**
Insider Ownership (%)	**3**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2025 Estimate	**-1.1**
P/E using 2026 Estimate	**-1.7**

Risk Level	**Above Avg.**
Type of Stock	**Small-Value**
Industry	**Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue
(in millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	0.3 A	0.2 A	0.1 A	0.2 A	0.8 A
2024	0.1 A	0.0 A	0.0 A	0.2 E	0.5 E
2025					1.0 E
2026					1.0 E

Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	-$5.74 A	-$3.56 A	-$2.56 A	-$3.41 A	-$12.66 A
2024	-$2.91 A	-$1.31 A	-$0.78 A	-$0.95 E	-$4.65 E
2025					-$2.93 E
2026					-$1.86 E

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW


Business Update

Additional Positive Data for IIS of HyBryte in CTCL

On January 14, 2025, Soligenix, Inc. (SNGX) announced additional positive data from the open-label, investigator-initiated study (IIS) of HyBryte (synthetic hypericin) for patients with cutaneous T cell lymphoma (CTCL) for up to 12 months. During the study patients are treated twice a week and the protocol allows for the potential transition to a "real-world" setting with at-home use. The trial is being sponsored by Dr. Ellen Kim, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and Professor of Dermatology at the Hospital of the University of Pennsylvania and is being funded by a $2.6 million Orphan Products Development Grant from the FDA.

Thus far, nine patients have been enrolled into the study, with six patients having completed at least 18 weeks of therapy. Of those six, five have achieved "treatment success", which is defined in the study protocol as a ≥50% improvement in the cumulative mCAILS (modified Composite Assessment of Index Lesion Severity) score compared to baseline. Of the five treatment successes, three were achieved within the first 12 weeks of treatment and two have achieved a "complete response" by 18 weeks. Of the remaining patients, two recently started the study and two had to drop from the study for logistical reasons, although one of those showed a substantial improvement (>30%) by 18 weeks. Importantly, HyBryte continues to be safe and well tolerated.

To put these results into context, the following chart shows the response rate seen for HyBryte treatment from different studies that examined various treatment lengths. The data shows that there appears to be a direct correlation between treatment length and response rate, and extrapolating these results to the recently initiated Phase 3 FLASH2 trial (in which patients will receive treatment twice a week for 18 weeks) shows that a response rate of approximately 80% for those treated with HyBryte is likely.



*Treatment not continuous, applied in cycles in FLASH Study

Source: Soligenix, Inc.

Conclusion

We continue to be very encouraged by the results from studies testing HyBryte as a treatment for CTCL. The results announced today show that extended treatment with HyBryte is leading to improved outcomes for patients. We anticipate additional updates from this study as more data becomes available. In addition, the company recently initiated the Phase 3 FLASH2 trial, and we expect updates on the progress of that trial later in 2025. With no changes to our model our valuation remains at $35 per share.


PROJECTED FINANCIALS

Soligenix, Inc.	2023 A	Q1 A	Q2 A	Q3 A	Q4 E	2024 E	2025 E	2026 E
License Revenue	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Grant/Contract Revenue	$0.8	$0.1	$0.0	$0.0	$0.2	$0.3	$1.0	$1.0
HyBryte	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Public Health Solutions	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Total Revenues	**$0.8**	**$0.1**	**$0.0**	**$0.0**	**$0.2**	**$0.3**	**$1.0**	**$1.0**
Cost of Revenue	$0.7	$0.1	$0.0	$0.0	$0.2	$0.3	$0.8	$0.8
Gross Income	**$0.1**	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$0.2**	**$0.2**
Gross Margin	*11.6%*	*0.0%*	*0.0%*	*#DIV/0!*	*10.0%*	*6.3%*	*20.0%*	*20.0%*
Research & Development	$3.3	$1.1	$0.5	$1.0	$1.0	$3.6	$4.0	$4.2
General & Administrative	$4.5	$1.0	$1.2	$0.9	$1.2	$4.4	$5.0	$5.3
Other Expenses	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Operating Income	($7.7)	($2.1)	($1.7)	($1.9)	($2.2)	($7.9)	($8.8)	($9.3)
Operating Margin	-	-	-	-	-	-	-	-
Other Income (Net)	$0.2	$0.2	$0.1	$0.1	$0.0	$0.4	$0.0	$0.0
Pre-Tax Income	**($7.9)**	**($1.9)**	**($1.6)**	**($1.7)**	**($2.2)**	**($7.5)**	**($8.8)**	**($9.3)**
Net Taxes (benefit)	$1.8	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Tax Rate	*22.4%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*
Reported Net Income	**($6.1)**	**($1.9)**	**($1.6)**	**($1.7)**	**($2.2)**	**($7.5)**	**($8.8)**	**($9.3)**
Net Margin	-	-	-	-	-	-	-	-
Reported EPS	**($12.66)**	**($2.91)**	**($1.31)**	**($0.78)**	**($0.95)**	**($4.65)**	**($2.93)**	**($1.86)**
YOY Growth	-	-	-	-	-	-	-	-
Basic Shares Outstanding	0.5	0.7	1.3	2.2	2.3	1.6	3.0	5.0

Source: Zacks Investment Research, Inc. *David Bautz, PhD*

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

HISTORICAL STOCK PRICE



Source: Zacks Small Cap Research

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.